{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019685","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.214757+00:00","generated_at":"2026-06-15T09:30:44.625587+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet Bio Q1 net loss $30.9M vs prior-year net income; cash $231.6M","bullets":["Net loss of $30.9M ($0.72 loss per share) vs net income of $4.6M in Q1 2022.","Cash, cash equivalents and investments $231.6M at March 31, expected to fund ops into H1 2025.","R&D expenses rose to $26.8M from $13.5M YoY, driven by increased CDMO and headcount costs.","Plan to discuss FDA path for ADI-001 pivotal study in Q2 2023; initiate study in Q4 2023.","ADI-270 preclinical data at ASGCT May 18; IND for ADI-925 expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019685","json":"https://secwatch.observer/filing/0000950170-23-019685.json","markdown":"https://secwatch.observer/filing/0000950170-23-019685.md","text":"https://secwatch.observer/filing/0000950170-23-019685.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023019685/0000950170-23-019685-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023019685/acet-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:30:44.625587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcd9163d6fe111e5b1e798175bb26386b1ed5213","claim":"Adicet Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023 was $30.9 million, or a net loss of $0.72 per basic and diluted share, EPS $0.72 per basic and diluted share.","evidence_excerpt":"Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023019685/0000950170-23-019685-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2023 was $30.9 million, or a net loss of $0.72 per basic and diluted share"},{"label":"EPS","value":"$0.72 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}